Compare SBAC & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBAC | HUMAW |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | N/A |
| IPO Year | 1999 | N/A |
| Metric | SBAC | HUMAW |
|---|---|---|
| Price | $190.78 | $0.15 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $238.13 | N/A |
| AVG Volume (30 Days) | ★ 792.8K | 14.2K |
| Earning Date | 11-03-2025 | 03-21-2025 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 25.44 | N/A |
| EPS | ★ 7.95 | N/A |
| Revenue | ★ $2,789,256,000.00 | N/A |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $24.11 | ★ N/A |
| Revenue Growth | ★ 4.82 | N/A |
| 52 Week Low | $185.13 | $1.18 |
| 52 Week High | $245.16 | $1.34 |
| Indicator | SBAC | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 44.95 |
| Support Level | $187.61 | $0.11 |
| Resistance Level | $194.16 | $0.15 |
| Average True Range (ATR) | 3.35 | 0.03 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 60.58 | 91.78 |
SBA Communications owns a portfolio of about 45,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by the top few mobile carriers. It owns more than 17,000 towers in the US, which account for about 75% of leasing revenue. Internationally, SBA's largest presence is in Brazil, where it owns roughly 10,000 towers. SBA operates as a real estate investment trust.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.